Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE versus PROMETHAZINE HYDROCHLORIDE PLAIN.
CETIRIZINE HYDROCHLORIDE vs PROMETHAZINE HYDROCHLORIDE PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1-receptor antagonist; inhibits histamine-mediated allergic and inflammatory responses.
Promethazine is a phenothiazine derivative that acts as a competitive antagonist at histamine H1 receptors, thereby blocking the effects of histamine. It also has anticholinergic, antiemetic, and sedative properties. In the CNS, it inhibits the chemoreceptor trigger zone and vestibular apparatus, contributing to its antiemetic effect.
5-10 mg orally once daily; maximum 10 mg per day.
Adults: 25 mg orally or intramuscularly every 4 to 6 hours as needed; for motion sickness, 25 mg taken 30-60 minutes before departure, then every 12 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 8-11 hours in healthy adults; prolonged in renal impairment (up to 20-30 hours in moderate to severe impairment).
Terminal elimination half-life is approximately 10-19 hours in adults (mean ~16 hours). In children, half-life is shorter (~7-14 hours). Clinical context: Once-daily dosing may be insufficient for continuous sedation; requires every 6-8 hour dosing for sustained effect.
Primarily renal (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~70% of elimination, with 20-30% as unchanged drug in urine. Fecal excretion is minimal (~5%).
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic